Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast

Clinical Cancer Research

Volumn 5, Issue 5, 1999, Pages 1041-1056

  Brown, Lawrence F ^a,b   Guidi, Anthony J ^a   Schnitt, Stuart J ^a   Van De Water, Livingston ^a   Iruela Arispe, Maria Luisa ^a   Yeo, Tet Kin ^a   Tognazzi, Kathi ^a   Dvorak, Harold F ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECORIN; FIBRONECTIN; THROMBOSPONDIN 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VERSICAN;

ANGIOGENESIS; ARTICLE; BREAST CARCINOMA; CARCINOMA IN SITU; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; INVASIVE CARCINOMA; METASTASIS; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VASCULARIZATION;

ADENOCARCINOMA, MUCINOUS; BIOLOGICAL MARKERS; BIOPSY; BREAST; BREAST NEOPLASMS; CARCINOMA; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; COLLAGEN; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; EPITHELIAL CELLS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FIBROCYSTIC BREAST DISEASE; FIBRONECTINS; FROZEN SECTIONS; HUMANS; IN SITU HYBRIDIZATION; LECTINS, C-TYPE; LYMPHATIC METASTASIS; LYMPHOKINES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN ISOFORMS; PROTEOCHONDROITIN SULFATES; PROTEOGLYCANS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA, MESSENGER; RNA, NEOPLASM; STROMAL CELLS; THROMBOSPONDIN 1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTORS; VERSICANS;

EID: 0032933778     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Folkman, J., and Shing, Y. Angiogenesis. J. Biol. Chem., 267: 10931-10934, 1992.
2. Weidner, N., Semple, J. P., Welch, W. R., and Folkman, J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N. Engl. J. Med., 324: 1-8, 1991.
3. Weidner, N., Folkman, J., Possa, F., Bevilacqua, P., Allred, E. N., Moore, D. H., Meli, S., and Gasparini, G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. (Bethesda), 84: 1875-1887, 1992.
4. Ashkenas, J., Muschler, J., and Bissell, M. J. The extracellular matrix in epithelial biology: shared molecules and common themes in distant phyla. Dev. Biol., 180: 433-444, 1996.
5. Iozzo, R. V. Tumor stroma as a regulator of neoplastic behavior. Lab. Invest., 73: 157-160, 1995.
6. Senger, D. R. Molecular framework for angiogenesis: a complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines. Am. J. Pathol., 149: 1-7, 1996.
7. Dvorak, H. F., Nagy, J. A., and Dvorak, A. M. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells, 3: 77-85, 1991.
8. Dvorak, H. F., Brown, L. F., Detmar, M., and Dvorak, A. M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am. J. Pathol., 146: 1029-1039, 1995.
9. Good, D. J., Polverini, P. J., Rastinejad, F., Le Beau, M. M., Lemons, R. S., Frazier, W. A., and Bouck, N. P. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA, 87: 6624-6628, 1990.
10. Iruela-Arispe, M. L., Bornstein, P., and Sage, H. Thrombospondin exerts an antiangiogenic effect on tube formation by endothelial cells in vitro. Proc. Natl. Acad. Sci. USA, 88: 5026-5030, 1991.
11. Tolsma, S. S., Volpert, O. V., Good, D. J., Frazier, W. A., Polverini, P, J., and Bouck, N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J. Cell Biol., 122: 497-511, 1993.
12. George, E. L., Baldwin, H. S., and Hynes, R. O. Fibronectins are essential for heart and blood vessel morphogenesis but are dispensable for initial specification of precursor cells. Blood, 90: 3073-3081, 1997.
13. Bowersox, J. C., and Sorgente, N. Chemotaxis of aortic endothelial cells in response to fibronectin. Cancer Res., 42: 2547-2551, 1982.
14. Madri, J. A., Pratt, B. M., and Tucker, A. M. Phenotypic modulation of endothelial cells by transforming growth factor-β depends upon the composition of the extracellular matrix. J. Cell Biol., 106: 1375-1384, 1988.
15. Nicosia, R. F., Bonnano, E., and Smith, M. Fibronectin promotes the elongation of microvessels during angiogenesis in vitro. J. Cell. Physiol., 154: 654-661, 1993.
16. Yamaguchi, Y., Mann, D. M., and Rouslahti, E. Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature (Lond.), 346: 281-284, 1990.
17. Takeuchi, Y., Kodama, Y., and Matsumoto, T. Bone matrix decorin binds transforming growth factor-β and enhances its bioactivity. J. Biol. Chem., 269: 32634-32638, 1994.
18. De Luca, A., Santra, M., Baldi, A., Giordano, A., and Iozzo, R. V. Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J. Biol. Chem., 271: 18961-18965, 1996.
19. Elston, C. W., and Ellis, I. O. Pathological prognostic factors in breast cancer. 1. The value of histologic grade in breast cancer. Experience from a large study with long term follow-up. Histopathology, 19: 403-410, 1991.
20. ffrench-Constant, C., Van De Water, L., Dvorak, H. F., and Hynes, R. O. Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat. J. Cell Biol., 109: 903-914, 1989.
21. Brown, L. F., Berse, B., Tognazzi, K., Manseau, E. J., Van De Water, L., Senger, D., Dvorak, H., and Rosen, S. Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int., 42: 1457-1461, 1992.
22. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Senger, D. R., and Dvorak, H. F. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res., 53: 4727-4735, 1993.
23. Brown, L. F., Dubin, D., Lavigne, L., Logan, B., Dvorak, H. F., and Van De Water, L. Macrophages and fibroblasts express embryonic fibronectins during cutaneous wound healing. Am. J. Pathol., 142: 793-801, 1993.
24. de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N., and Williams, L. T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (Washington DC), 255: 989-991, 1992.
25. Terman, B. I., Dougher Vermazen, M., Carrion, M. E., Dimitrov, D., Armellino, D. C., Gospodarowicz, D., and Bohlen, P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem. Biophys. Res. Commun., 187: 1579-1586, 1992.
26. Dvorak, H. F., Orenstein, N. S., Carvalho, A. C., Churchill, W. H., Dvorak, A. M., Galli, S. J., Feder, J., Bitzer, A. M., Rypysc, J., and Giovinco, P. Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J. Immunol., 122: 166-174, 1979.
27. Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., and Dvorak, H. F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (Washington DC), 219: 983-985, 1983.
28. Keck, P. J., Hauser, S. D., Krivi, G., Sanzo, K., Warren, T., Feder, J., and Connolly, D. T. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science (Washington DC), 246: 1309-1312, 1989.
29. Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V., and Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (Washington DC), 246: 1306-1309, 1989.
30. Gospodarowicz, D., Abraham, J. A., and Schilling, J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc. Natl. Acad. Sci. USA, 86: 7311-7315, 1989.
31. Ferrara, N., and Henzel, W. J. Pituitary follicular cells secrete: a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun., 161: 851-858, 1989.
32. Pepper, M. S., Ferrara, N., Orci, L., and Montesano, R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem. Biophys. Res. Commun., 181: 902-906, 1991.
33. Unemori, E. N., Ferrara, N., Bauer, E. A., and Amento, E. P. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J. Cell Physiol., 153: 557-562, 1992.
34. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillet, N., Phillips, H. S., and Ferrara, N. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumor growth in vivo. Nature (Lond.), 562: 841-844, 1993.
35. Millauer, B., Shawver, L. K., Plate, K. H., Risau, W., and Ullrich, A. Glioblastoma growth inhibited in vivo by a dominant-negative Elk-1 mutant. Nature (Lond.), 367: 576-579, 1994.
36. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Guidi, A. J., Dvorak, H. F., Senger, D. R., Connolly, J. L., and Schnitt, S. J. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol., 26: 86-91, 1995.
37. Toi, M., Hoshina, S., Takayanagi, T., and Tominaga, T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn. J. Cancer Res., 85: 1045-1049, 1994.
38. Anan, K., Morisaki, T., Katano, M., Ikubo, A., Kitsuki, H., Uchiyama, A., Kuroki, S., Tanaka, M., and Torisu, M. Vascular endothelial growth factor and platelet derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Surgery (St. Louis). 119: 333-339, 1996.
39. Gasparini, G., Toi, M., Gion, M., Verderio, P., Dittadi, R., Hanatani, M., Matsubara, I., Vinante, O., Bonoldi, E., and Boracchi, P. Prognostic significance of vascular endothelial growth factor protein in node negative breast carcinoma. J. Natl. Cancer Inst. (Bethesda), 89: 139-147, 1997.
40. Guidi, A. J., Schnitt, S. J., Fischer, L., Tognazzi, K., Harris, J. R., Dvorak, H. F., and Brown, L. F. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer (Phila.), 80: 1945-1953, 1997.
41. Weinstat-Saslow, D. L., Zabrenetzky, V. S., VanHoutte, K., Frazier, W. A., Roberts, D. D., and Steeg, P. S. Transfection of thrombospondin I complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res., 54: 6504-6511, 1994.
42. Wong, S. Y., Purdie, A. T., and Han, P. Thrombospondin and other possible related matrix proteins in malignant and benign breast disease. An immunohistochemical study. Am. J. Pathol., 140: 1473-1482, 1992.
43. Tuszynski. G. P., and Nicosia, R. F. Localization of thrombospondin and its cysteine-serine-valine-threonine-cysteine-glycine-specific receptor in human breast carcinoma. Lab. Invest., 70: 228-233, 1994.
44. Clezardin, P., Frappart, L., Clerget, M., Pechoux, C., and Delmas, P. D. Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic and neoplastic human breast. Cancer Res., 53: 1421-1430, 1993.
45. Bertin, N., Clezardin, P., Kubiak, R., and Frappart, L. Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissue: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia. Cancer Res., 57: 396-399, 1997.
46. Legace, R., Grimaud, J. A., Schurch, W., and Seemayer, T. A. Myofibroblastic stromal reaction in carcinoma of the breast: variations of collagenous matrix and structural glycoproteins. Virchows Arch. A Pathol. Anat. Histopathol., 408: 49-59, 1985.
47. Olsen, E. B., Trier, K., Eldov, K., Ammitzboll, T., and Ammitzboll, T. Glycosaminoglycans in human breast cancer. Acta Obstet. Gynecol. Scand., 67: 539-542, 1988.
48. Marotta, M., Vecchione, R., Martino, G., D'Armiento, F. P., De Cesare, M., and Rosati, P. Glycosaminoglycan enriched extracellular matrix surrounds intraductal carcinoma of the breast. Appl. Pathol., 3: 179-185, 1985.
49. Takeuchi, J., Sobue, M., Sato, E., Shamoto, M., and Miura, K. Variation in glycosaminoglycan components of breast tumors. Cancer Res., 36: 2133-2139, 1976.
50. Nara, Y., Kato, Y., Torii, Y., Tsuji, Y., Nakagaki, S., Goto, S., Isobe, H., Nakashima, N., and Takeuchi, J. Immunohistochemical localization of extracellular matrix components in human breast tumors with special reference to PG-M/versican. Histochem. J., 29: 21-30, 1997.
51. Alini, M., and Losa, G. A. Partial characterization of proteoglycans isolated from neoplastic and nonneoplastic human breast tissue. Cancer Res., 51: 1443-1447, 1991.
52. Cristensen. L. The distribution of fibronectin, laminin and tetranectin in human breast cancer with special attention to the extracellular matrix. Acta Pathol. Microbiol. Scand. Suppl., 26: 1-39, 1992.
53. Gould, V. E., Koukoulis, G. K., and Virtanen, I. Extracellular matrix proteins and their receptors in the normal, hyperplastic and neoplastic breast. Cell Differ. Dev., 32: 409-416, 1990.
54. Koukoulis, G. K., Howeedy, A. A., Korhonen, M., Virtanen, I., and Gould, V. E. Distribution of tenascin, cellular fibronectins and integrins in the normal, hyperplastic and neoplastic breast. J. Submicrosc. Cytol. Pathol., 25: 285-295, 1993.
55. Kaczmarek, J., Castellani, P., Nicolo, G., Spina, B., Allemani, G., and Zardi, L. Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int. J. Cancer, 59: 11-16, 1994.
56. Yoshida, T., Matsumoto, E., Hanamura, N., Kalembeyi, I., Katsuta, K., Ishihara, A., and Sakakura, T. Co-expression of tenascin and fibronectin in epithelial and stromal cells of benign lesions and ductal carcinomas in the human breast. J. Pathol., 182: 421-428, 1997.
57. Lorke, D., and Moller, P. The early appearance of fibronectin in the course of metastatic tumor growth in lymph nodes. J. Cancer Res. Clin. Oncol., 709: 65-71, 1985.
58. Hynes, R. O. Fibronectins. In: A. Rich (ed.), Springer Series in Molecular Biology, p. 546. New York: Springer-Verlag, 1990.
59. ffrench-Constant, C. Alternative splicing of fibronectin: many different proteins but few different functions. Exp. Cell Res., 221: 261-271, 1995.
60. Pujuguet, P., Hammann, A., Moutet, M., Samuel, J. L., Martin, F., and Martin, M. Expression of fibronectin EDA+ and EDB+ isoforms by human and experimental colorectal cancers. Am. J. Pathol., 148: 579-592, 1996.